rewirebio.iobenchmarks
Source

Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

43556_2026_538_MOESM1_ESM.docx, publisher supplementary file · Peer-reviewed

DOI: 10.1186/s43556-026-00538-w

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
Fragmentia-AI WGS, high-TF-only fine-tuningAUROC (all cancers vs non-cancer)0.769 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high-TF-only fine-tuning on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high-TF-only fine-tuningAUROC (high-TF (> 5%) cancers vs non-cancer)0.988 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high-TF-only fine-tuning on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high-TF-only fine-tuningAUROC (low-TF (< 3%) cancers vs non-cancer)0.652 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high-TF-only fine-tuning on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high-TF-only fine-tuningAUROC (medium-TF (3-5%) cancers vs non-cancer)0.905 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high-TF-only fine-tuning on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high-TF-only fine-tuningAUROC (high-TF cancers vs non-cancer (training cohort contains only high-TF cancers for this scheme))0.982 unitlessFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high-TF-only fine-tuning on the training cohort (resubstitution)
Fragmentia-AI WGS, high/medium-TF sequential fine-tuningAUROC (low-TF (< 3%) cancers vs non-cancer)0.702 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium-TF sequential fine-tuning on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (all cancers vs non-cancer)0.929 unitlessDELFI cohort from FinaleDB as used by the Fragmentia-AI WGS paper (538 samples)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the external delfi cohort (finaledb)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, all cancers, at the predefined cutoff (98% specificity in the training cohort))0.78 fractionDELFI cohort from FinaleDB as used by the Fragmentia-AI WGS paper (538 samples)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the external delfi cohort (finaledb)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Specificity (non-cancer controls, at the predefined cutoff (98% specificity in the training cohort))0.92 fractionDELFI cohort from FinaleDB as used by the Fragmentia-AI WGS paper (538 samples)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the external delfi cohort (finaledb)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (all cancers vs non-cancer)0.930 unitlessFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (high-TF (> 5%) cancers vs non-cancer)0.984 unitlessFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (low-TF (< 3%) cancers vs non-cancer)0.910 unitlessFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (medium-TF (3-5%) cancers vs non-cancer)0.958 unitlessFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, all cancers, at the predefined cutoff (98% specificity in the training cohort))0.58 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, high-TF (> 5%) cancers, at the predefined cutoff (98% specificity in the training cohort))0.91 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) cancers, at the predefined cutoff (98% specificity in the training cohort))0.46 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage I/II cancers, at the predefined cutoff (98% specificity in the training cohort))0.391 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage III/IV cancers, at the predefined cutoff (98% specificity in the training cohort))0.708 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, medium-TF (3-5%) cancers, at the predefined cutoff (98% specificity in the training cohort))0.72 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Specificity (non-cancer controls, at the predefined cutoff (98% specificity in the training cohort))0.97 fractionFragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the independent test cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (all cancers vs non-cancer)0.917 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (low-TF (< 3%) cancers vs non-cancer)0.884 unitlessFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, all cancers, at the predefined cutoff (98% specificity in the training cohort))0.61 fractionFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage I/II cancers, at the predefined cutoff (98% specificity in the training cohort))0.397 fractionFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage III/IV cancers, at the predefined cutoff (98% specificity in the training cohort))0.683 fractionFragmentia-AI WGS internal validation cohort (2,043 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the internal validation cohort by ichorcna tumour fraction
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (all cancers vs non-cancer)0.924 unitlessFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the training cohort (resubstitution)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)AUROC (low-TF (< 3%) cancers vs non-cancer)0.905 unitlessFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the training cohort (resubstitution)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, all cancers, at the predefined cutoff (98% specificity in the training cohort))0.58 fractionFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the training cohort (resubstitution)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage I/II cancers, at the predefined cutoff (98% specificity in the training cohort))0.396 fractionFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the training cohort (resubstitution)
Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Recall (sensitivity, low-TF (< 3%) stage III/IV cancers, at the predefined cutoff (98% specificity in the training cohort))0.716 fractionFragmentia-AI WGS training cohort (3,695 samples, 0.1x ULP-WGS)Fragmentia-AI WGS high/medium/low-TF sequential fine-tuning (final model) on the training cohort (resubstitution)

Claims

Statements this source supports, each with where in the source it was checked.

  • Evidence summary: plasma ctDNA fragmentomics workflows: Summary Eight sources compare plasma cfDNA fragmentomic workflows on retrospective case-control cohorts. None is a prospective screening study and none measures clinical benefit. Cristiano et al. 2019, the DELFI developers, report 73% sensitivity (152 of 208 cancers) at a reported 98% specificity for DELFI in repeated cross-validation against 215 healthy individuals. Hou et al. 2024 re-implemented ten published fragmentation patterns and DELFI with one support vector machine each on the same cohort. They are independent of every pattern except IFS, which their corresponding author developed. In 10 x 10-fold cross-validation, pan-cancer AUC within open chromatin regions ranged from 0.8741 (fragment length) to 0.9736 (5' end motif), and their DELFI re-implementation reached 0.9575. Rankings changed on independent cohorts. On 46 lung cancers and 385 healthy individuals, with a model trained on 12 lung cancers, the end-motif model fell to AUC 0.5355 and sensitivity 0.0652 at 95% specificity, while fragment size distribution reached 0.9386 and 0.7174. Hou et al.'s supplementary pan-cancer and liver cancer sensitivities conflict with other tables of the same file and are not shown. Wang et al. 2026, the UNITE developers, stratified cancers by ichorCNA tumour fraction in pooled public and new 0.1x data that include samples of the DELFI and Jiang et al. cohorts used above. For cancers with an estimated tumour fraction of 3% or less, cross-validated AUC was 0.878 for all five features combined, 0.873 for fragment length, 0.857 for the SD of length counts, 0.736 for copy number, 0.715 for the C/T end-motif ratio and 0.651 for the short/long ratio, against 0.603 for a classifier using the ichorCNA tumour fraction alone, which detected 0.058 of these cancers at 95% specificity. For cancers with an estimated fraction above 3% and up to 10%, the ichorCNA classifier reached 0.983, above the combined model (0.962) and copy number alone (0.926). The extracted UNITE tables give sensitivity at a fixed specificity only for the ichorCNA comparator; the fragmentomic models' values are in a sheet not yet extracted. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, scored fragment length and fragment endpoint classifiers from 30x cfDNA whole-genome sequencing on the same CCGA substudy 1 participants as their methylation, copy-number and variant classifiers, at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers the fragment length classifier detected 29% (95% CI 25% to 34%) and the fragment endpoint classifier 18% (15% to 22%), against 34% for whole-genome methylation analysed double-blinded; both fragment classifiers were developed after the validation set had been unblinded, so these are not blinded validation results, and no tumour-fraction-stratified sensitivity is printed. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, computed fragmentomic features from cfMeDIP-seq reads, which are enriched for methylated fragments rather than drawn from whole-genome sequencing, and report means over 10 fold models. On an independent paired-end validation set, a fragment-ratio classifier reached AUC 0.848 and detected 0.533 of cancers at 99% specificity, and fragment ratios combined with methylation reached 0.954 and 0.766. The validation set has 17 healthy controls, so its 99% specificity allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in its sensitivities. Three of the five classifiers that include end motifs scored below AUC 0.5 there, which the authors attribute to healthy controls processed with a different laboratory protocol, so validation results for all five are not shown. Helzer et al. 2025 (Nature Communications) compared twelve fragmentomic metrics adapted to targeted exon panels, including the authors' own fragment-size entropy metrics, their combination and Griffin, with one classifier and shared folds, on plasma from patients with metastatic cancer. The healthy-versus-cancer one-vs-rest AUROC ranged from 0.835 (open-chromatin entropy) to 0.989 (first-exon depth) in a UW cohort of 404 cancers and 27 healthy donors, with Griffin at 0.944, and from 0.951 to 1.000 in public GRAIL panel data from 151 cancers and 47 healthy donors. In a developer comparison on 0.1x whole-genome sequencing (Cell Reports Medicine 2026), a fragment-level language model (Fragmentia-AI) reached AUC 0.9561 on a held-out set of unstated size, against 0.9209 to 0.935 for the developers' re-implementation of DELFI features and 0.881 to 0.8863 for Griffin features under three classifiers. The same company's whole-genome model (Molecular Biomedicine 2026), on an independent test cohort of 2,952 cancers and 3,044 non-cancer controls, reached AUC 0.910 for cancers with an ichorCNA tumour fraction below 3% and detected 0.46 of them at a cutoff set to 98% specificity in training (observed test specificity 0.97); among those low-fraction cancers it detected 0.391 at stage I/II (637 of 1,628) and 0.708 at stage III/IV (345 of 487). Its tumour-fraction strata are ichorCNA estimates, no comparator was run on its cohorts, and its training cohort has the same number of non-cancer controls (1,245) as the Cell Reports Medicine cohort, so the two studies may share samples. Three of these four studies report on their authors' own method, and in the fourth the authors' own entropy metrics are among those compared. Cohorts, feature implementations, classifiers and validation designs differ, so no value is comparable across sources. (amp-20261007-ctdna-fragmentomics-source: result amp-20261007-ctdna-fragmentomics-result; ctdnafrag-20261009-source-hou2024: Table 1, P24 and P44; ctdnafrag-20261009-source-hou2024-supporting-information: Table S3; ctdnafrag-20261009-source-wang2026-data-file-s2: STATS_xgb_x1-x6 and STATS_lr; ctdnafrag-20261009-source-wang2026: Results and Methods; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4c and Fig.4d; ctdnalit-20261011-helzer2025-source-supplementary-information: Supplementary Tables S1 and S2, 'Normal' columns; ctdnalit-20261011-helzer2025-source-article: Results P5-P8; ctdnalit-20261011-fragmentia2026-source-document-s1: Table S5; ctdnalit-20261011-fragmentia2026-source-article: Results P39-P44; ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Tables S1 and S4)
  • Relevance of ctdnalit-20261011-fragmentiawgs2026-protocol-delfi to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Fragmentia-AI WGS paper: External DELFI cohort (FinaleDB) (ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; Methods P40-P60; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Table S4)
  • Relevance of ctdnalit-20261011-fragmentiawgs2026-protocol-test to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Fragmentia-AI WGS paper: Independent test cohort by ichorCNA tumour fraction (ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; Methods P40-P60; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Table S4)
  • Relevance of ctdnalit-20261011-fragmentiawgs2026-protocol-validation to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?": Assessed by Fragmentia-AI WGS paper: Internal validation cohort by ichorCNA tumour fraction (ctdnalit-20261011-fragmentiawgs2026-source-article: Results P8-P21; Methods P40-P60; ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1: Table S4)

Models, benchmarks and other records

Configurations (3)

Protocols (4)

Datasets (4)

Evaluations (7)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

20 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive note
Not archived: the 2.5 MB DOCX is mostly figure images and is a stable publisher object pinned by hash.
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://static-content.springer.com/esm/art%3A10.1186%2Fs43556-026-00538-w/MediaObjects/43556_2026_538_MOESM1_ESM.docx
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1186/s43556-026-00538-w
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
CC-BY-4.0
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/vnd.openxmlformats-officedocument.wordprocessingml.document
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieval note
The same bytes are served inside the Europe PMC supplementaryFiles bundle for PMC13469060 (checked 2026-10-11T21:51:38Z).
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieval_note

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-11T21:52:25Z
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Source location
Table S4
Source metadata
Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9)

Original source ↗

No field-specific location recorded

Version: 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Retrieved: 2026-10-11T21:52:25Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Supplementary DOCX retrieved and hashed for the 2026-10-11 plasma ctDNA literature pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnalit-20261011-fragmentiawgs2026-source-supplementary-material-1

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.1186/s43556-026-00538-w
artifact url
https://static-content.springer.com/esm/art%3A10.1186%2Fs43556-026-00538-w/MediaObjects/43556_2026_538_MOESM1_ESM.docx
version
43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
retrieved at
2026-10-11T21:52:25Z
artifact sha256
df6f4b15b28075b1e45aa43ba426213bdc3ac2f6eda931937081e6e6055e85d0
doi
10.1186/s43556-026-00538-w
publication status
peer_reviewed
licence
CC-BY-4.0
media type
application/vnd.openxmlformats-officedocument.wordprocessingml.document
source locator
Table S4
retrieval note
The same bytes are served inside the Europe PMC supplementaryFiles bundle for PMC13469060 (checked 2026-10-11T21:51:38Z).
archive note
Not archived: the 2.5 MB DOCX is mostly figure images and is a stable publisher object pinned by hash.
Related records

    Suggest a correction